December, 06, 2024（Vientiane）After nearly three years of development from 2022 to 2024, RxLibra has helped Lao pharmaceutical industry open the door to the international market.

The following is our record of commitment to the industry and our clients over the years：

• How is start: Focus on accessibility-Driving the future of Laos’ pharmaceutical Industry
• How is going: Double “0” breakthrough! Laos BIGBEAR Pharmaceutical’s anti-cancer drugs are exported to ASEAN economies for the first time

In November and December 2024, upstream pharmaceutical companies in Laos will undergo mergers and reorganizations to form a stronger cartel alliance. They will be able to enter a wider international market.

From now on, RxLibra believes that our historical mission in Laos has been completed, and the next step will focus on the accessibility of medicines in the Southeast Asian market.

Outside of Laos’ pharmaceutical industry, China in East Asia has produced a large number of innovative drugs in the past five years, basically covering major types of cancer, and their cost-effectiveness is very obvious.

There is currently a clear generational gap between the medical field in Southeast Asia and China. While we maintain good relations with the Lao pharmaceutical industry.We plan to accelerate the penetration of China’s innovative technologies into Southeast Asia.This will be our next stage of development plan.

We have already confirmed our Chinese partners. All new products will be displayed on LienTeh . Lienteh will also make minor adjustments.

At this point, we would like to thank our customers and supply chain partners for their support over the past three years. We will continue to move forward.

About RxLibra

RxLibra is a pharmaceutical industry service provider established in Vientiane, Laos during the COVID-19 pandemic. Its purpose is to help the Lao pharmaceutical industry enter the economic cycle of the global market. Laos is one of the least developed countries in the world and enjoys the WTO’s drug patent control exemption. In the past few years, some pharmaceutical companies from India, China and Bangladesh have entered Laos to set up production bases, introduce technical talents from neighboring countries, and build production workshops that meet GMP standards. These start-up pharmaceutical companies hope to gradually enter the global market. RxLibra plays a similar role as a carrier in this process, responsible for promoting pharmaceutical companies in the early stages of development.

RxLibra will next focus on improving the accessibility of innovative Chinese drugs to patients in Southeast Asia.

Contact Us： info@rxlibra.com